Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30670
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDalli, Lachlan L-
dc.contributor.authorAndrew, Nadine E-
dc.contributor.authorKim, Joosup-
dc.contributor.authorCadilhac, Dominique A-
dc.contributor.authorSanfilippo, Frank M-
dc.contributor.authorThrift, Amanda G-
dc.contributor.authorNelson, Mark R-
dc.contributor.authorLannin, Natasha A-
dc.contributor.authorOlaiya, Muideen T-
dc.contributor.authorRyan, Olivia F-
dc.contributor.authorBooth, Brenda-
dc.contributor.authorGall, Seana-
dc.contributor.authorKilkenny, Monique F-
dc.date2022-
dc.date.accessioned2022-08-02T06:43:07Z-
dc.date.available2022-08-02T06:43:07Z-
dc.date.issued2022-09-
dc.identifier.citationResearch in social & administrative pharmacy : RSAP 2022; 18(9): 3542-3549en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30670-
dc.description.abstractIt is unclear whether survivors of stroke or transient ischemic attack (TIA) routinely receive, and understand, education about secondary prevention medications. To investigate whether survivors of stroke/TIA understand explanations about their prescribed prevention medications and associations with medication adherence, control of risk factors, and unmet needs. A survey was administered among survivors of stroke/TIA (random sample N = 1500) from the Australian Stroke Clinical Registry (Victoria and Queensland, 2016). Participants reported whether they understood explanations about each prescribed medication, as well as their unmet needs, perceived control of risk factors, and 30-day medication adherence. Linked pharmacy claims data were also used to determine medication adherence in the previous two years (proportion of days covered ≥80%). Outcomes were analyzed using multivariable logistic regression or multivariable negative binomial regression for frequency of unmet needs. Overall, 630/1455 eligible survivors completed the survey at ≈2.5 years post-admission (median age 69 years; 37% female). Most participants reported using prevention medications (76% antihypertensive; 84% antithrombotic; 76% lipid-lowering) but only 66-75% reported they understood explanations about their medication (75% antihypertensive; 66% antithrombotic; 74% lipid-lowering). Participants who understood explanations about their medication more often reported 30-day adherence for antihypertensive (adjusted odds ratios [aOR]: 1.96; 95% CI: 1.20-3.19), antithrombotic (aOR: 2.03; 95% CI: 1.31-3.14) and lipid-lowering medications (aOR: 1.73; 95% CI: 1.08-2.76). Similar associations were observed for antihypertensive and antithrombotic medications when pharmacy claims data were used to infer 2-year medication adherence. Understanding explanations about medications was also associated with perceived control of risk factors (hypertension: aOR: 11.08; 95% CI: 6.04-20.34; cholesterol aOR: 8.26; 95% CI: 4.72-14.47) and up to 33% fewer unmet needs related to secondary prevention. Expanded efforts are needed to improve the delivery of information about prevention medications to promote medication adherence, control of risk factors, and potentially prevent unmet needs following stroke/TIA.en
dc.language.isoeng
dc.subjectMedication adherenceen
dc.subjectMedication counsellingen
dc.subjectPatient understandingen
dc.subjectPatient-reported outcomesen
dc.subjectPharmacoepidemiologyen
dc.subjectStrokeen
dc.titleUnderstanding of medications and associations with adherence, unmet needs, and perceived control of risk factors at two years post-stroke.en
dc.typeJournal Articleen
dc.identifier.journaltitleResearch in social & administrative pharmacy : RSAPen
dc.identifier.affiliationDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia..en
dc.identifier.affiliationPeninsula Clinical School, Central Clinical School, Monash University, Frankston, VIC, Australia..en
dc.identifier.affiliationSchool of Population and Global Health, The University of Western Australia, Perth, WA, Australia..en
dc.identifier.affiliationStroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia..en
dc.identifier.affiliationMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia..en
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Healthen
dc.identifier.affiliationStroke Foundation, VIC, Australiaen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35093283/en
dc.identifier.doi10.1016/j.sapharm.2022.01.007en
dc.type.contentTexten
dc.identifier.orcid0000-0002-4079-0428en
dc.identifier.orcid0000-0001-8162-682Xen
dc.identifier.orcid0000-0003-4977-6742en
dc.identifier.orcid0000-0002-3375-287Xen
dc.identifier.pubmedid35093283
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Oct 1, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.